ArticleCancer gene therapy2026
Single-nucleus and spatial transcriptomics analyses reveal interplay between evolutionary dynamics and energy metabolism in primary cardiac lymphoma.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Primary cardiac lymphoma (PCL), a rare B-cell non-Hodgkin's lymphoma, has shown a rising incidence, yet the lack of clarity regarding its molecular basis continues to hinder the development of effective targeted therapies. In this study, we utilized single-nucleus RNA sequencing and Visium CytAssist spatial transcriptomics in two patients with PCL to examine the metabolic and immune landscape of PCL. Our data implicate chromosomal instability (CIN) as a potential driver of disease progression, likely by modulating cellular sensitivity to metabolic stress. Single-cell analysis identified five distinct malignant B-cell states, including a B3 subset defined by subclonal diversification and enriched fatty acid metabolism-MAPK signaling. NFYA was also noted as a transcription factor potentially involved in this lipid reprogramming. Spatial observations suggest that B3 cells may contribute to an immunosuppressive microenvironment, with the CD44-LGALS9 axis acting as a possible mediator of endothelial cell remodeling and T-cell suppression. Ultimately, this study provides fresh insights into the clonal evolution and metabolic adaptations of PCL. These findings suggest that fatty acid metabolic reprogramming and CD44-LGALS9-mediated immune evasion play roles in tumor maintenance within the cardiac environment, offering a preliminary basis for future targeted therapeutic intervention.
Indexed as
Identifiers
42174190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.